EnteroMedics

homesitemapcontact us

   search

 

   
 
 
   
   
 

Overview

 
 

About vBloc® Therapy

 
 

vBloc® Maestro® System

 
 

Obesity

 
 

Clinical Experience

 
 

     Obesity

 
 

     Diabetes

 
 

     Cardiovascular Disease

 

Publications

 
 

Clinical Experience in Cardiovascular Disease

Blood pressure normally rises and falls throughout the day. When it consistently stays too high for too long, it is called hypertension. Hypertension is an important public health challenge and the leading cause of cardiovascular disease worldwide. A recent estimate suggests that approximately 1 billion adults have hypertension (333 million in economically developed and 639 million in economically developing countries); the highest prevalence is in Eastern Europe and the Latin American/Caribbean region. About one in three American adults has high blood pressure or hypertension, and national surveys indicate the prevalence of hypertension in many countries is as high or higher than that identified in the United States.

People who suffer from obesity or diabetes are at risk for many illnesses, including hypertension. Having untreated hypertension can lead to serious health problems, including coronary heart disease, heart failure, stroke and kidney failure.

EnteroMedics® believes its proprietary VBLOC® vagal blocking therapy has the potential to be effective in the treatment of diabetes and hypertension associated with obesity. Literature suggests that vagal nerve signaling plays a key role in the control of blood glucose and blood pressure.

The Company believes that vBloc® Therapy may improve mean systolic and diastolic blood pressure in hypertensive patients. An evaluation of the blood pressure effects of vBloc® Therapy in the international feasibility trial, VBLOC-DM2 Enable, further explores the efficacy of vBloc® Therapy in this patient population.

Learn more about our clinical trial results >.